$2.20
0[0.00%]
Last update: 4:20PM Get Real Time Here
Lyell Immunopharma reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Analyze the earnings history of Lyell Immunopharma using advanced sorting and filters.
Date | time | ticker | Quarter | Prior EPS | Est EPS | Actual EPS | EPS Surprise | Prior Rev | Est Rev | Actual Rev | Rev Surprise | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|---|
05/10/2024 | PM | LYEL | Q1 | -$0.18 | -$0.21 | — | — | $65.00K | — | — | — | Get Alert |
02/28/2024 | PM | LYEL | Q4 | $0.00 | -$0.23 | -$0.17 | 26.09% | $48.39M | — | $13.00K | — | Get Alert |
11/07/2023 | PM | LYEL | Q3 | -$0.18 | -$0.25 | -$0.17 | 32.00% | $3.00K | — | $25.00K | — | Get Alert |
08/08/2023 | PM | LYEL | Q2 | -$0.04 | -$0.23 | -$0.04 | 82.61% | $35.74M | — | $27.00K | — | Get Alert |
05/04/2023 | PM | LYEL | Q1 | -$0.20 | — | -$0.18 | — | $553.00K | — | $65.00K | — | Get Alert |
02/28/2023 | PM | LYEL | Q4 | -$0.17 | — | $0.00 | — | $2.82M | — | $48.39M | — | Get Alert |
11/08/2022 | PM | LYEL | Q3 | -$0.15 | — | -$0.18 | — | $2.75M | — | $3.00K | — | Get Alert |
08/04/2022 | PM | LYEL | Q2 | -$0.89 | — | -$0.04 | — | $2.63M | — | $35.74M | — | Get Alert |
05/10/2022 | PM | LYEL | Q1 | — | — | -$0.20 | — | $2.44M | — | $553.00K | — | Get Alert |
03/29/2022 | PM | LYEL | Q4 | — | — | -$0.17 | — | — | — | $2.82M | — | Get Alert |
11/12/2021 | AM | LYEL | Q3 | -$1.78 | -$0.27 | -$0.15 | 44.44% | $1.07M | $2.30M | $2.75M | 19.78% | Get Alert |
08/12/2021 | PM | LYEL | Q2 | -$7.54 | — | -$0.89 | — | $3.12M | — | $2.63M | — | Get Alert |
Lyell Immunopharma (LYEL) is scheduled to report earnings on May 10, 2024. The last reported earnings were for reported on February 28, 2024 for Q4.
The Actual EPS was $-0.17, which beat the estimate of $-0.23.
The Actual Revenue was $13K, which beat the estimate of $0K.
Browse earnings estimates, EPS, and revenue on all stocks.